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Previous immunofluorescent studies showing deposits 
of immunoglobulin and complement at the cutaneous 
basement membrane zone have provided evidence sup-
porting a role for immune complexes in the pathogenesis 
of bullous pemphigoid. In this study the functional activ-
ity of the deposits has been examined using leukocyte 
attachment, a method for detecting and quantitating the 
biological activity of complement-activating immune 
complexes in tissues. When peripheral blood leukocytes 
suspended in serum complement were incubated with 
cryostat sections of lesional and adjacent normal-~p­
pearing skin from 9 patients with pemphigoid, skin from 
11 normal controls and lesional skin from 14 nonpem-
phigoid disease controls there was significantly greater 
attachment of leukocytes to the basement membrane 
zone of lesi'onal bullous pemphigoid skin compared to 
normal-appearing pemphigoid skin and skin of both con-
trol groups. A significant reduction in attachment in the 
absence of serum complement suggested the reaction 
was dependent on activation of complement by tissue-
deposited complexes. Although leukocyte attachment 
was greater in lesional than normal-appearing pemphi-
goid skin, a comparison of the incidence and intensity of 
cutaneous IgG and complement immunofluorescence be-
tween the 2 groups showed no significant differences. 
Furthermore, no correlation between leukocyte attach-
ment and serum titers of immunoglobulin G or comple-
ment-binding anti-basement membrane zone a,ntibodies 
was observed. These results suggest that immune reac-
tants in lesional pemphigoid skin are functional comple-
ment-activating immune complexes, that differences ex-
ist between the activity of complexes in lesional and 
normal-appearing pemphigoid skin and may explain 
why lesions develop at some sites and not others. 
· There is abundant indirect evidence supporting the proposal 
that complement (C)-activating immune complexes may be 
important in the pathogenesis . of cutaneous inflammation in 
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bullous pemphigoid (BP) (1]. Results of studies us ing immu-
nofluorescent methods for the detection of immune reactants 
h ave shown deposits of immunoglobulin (Ig) and C at the 
basement membrane zone (BMZ) in both normal-appearing 
a nd lesional skin [2-4], C-binding anti-BMZ antibiodies in sera 
[5] and biologically active C fragments in blister fluids [6- 8]. 
Although these observations support a role for immune com-
plexes in the disease, it has not been directly shown that the 
immune reactants at the BMZ are components of functional 
complexes nor has it been determined why inflammation de-
velops at some sites of Ig and C deposition and not others. 
These questions, we feel, are critical to the proposed pathogen-
esis of the disease. 
In this study we used a recently described method, leukocyte 
attachment (LA) which has been shown effective in detecting 
and quantitating C-activating, immune complexes deposited in 
tissues in vivo and in vitro [9-11]. The method was used to 
determine: (1) if biologically functional immune complexes are 
present at the BMZ in skin of patients with active BP and (2) 
whether or not quantitative differences in function can be 
detected between lesional and adjacent normal-appearing skin. 
Furthermore, an attempt has been made to determine the 
relationship between functional immune complex activity and 
results of immunofluorescent studies of immune reactants in 
tissue and sera. 
MATERIALS AND METHODS 
Shin 
Four groups of skin samples were used in these studies. Two groups 
consisted of paired biopsies obtained simultaneously from the prebul-
lous macular or papular erythematous lesional skin (BPL) and adjacent, 
2 em away, clinicaUy normal-appearing skin (BPN) from 9 patients 
wilh BP. All patients were diagnosed by established clinical, histo\ogi 
and immunofluorescent criter ia [1 2]. Sk in samples were also obtained 
from 2 control groups. One control group consisted of skin from 11 
normal humans (NS). Skin in this group was obtained [rom adult 
volunteers (5) and from neonatal foreskin (6). A second control group 
consisted of lesional macular or papular erythematous skin from 14 
patients with a variety of active inflammatory diseases (DS). Included 
in this group were biopsies from paLien ts with eczema (5), erythema 
mu lliforme (2) , hypersensitivity vasculitis (2} , urticaria (1}, dermalo-
myositis (1), papulru· dermatitis of pregnancy (l) , Sweet's syndrome (1) 
and immunofluorescent-negative chronic bullous disease of childhood 
l. All samples were obtained afler informed consenl by 3-4 mm punch 
biopsies under 1% xylocaine anesthesia or routine circumcision. Sam-
ples were immediately frozen in liquid N2, mounted in OCT compound 
(Ames, Co., Elkhart, IN) and stored frozen at -70°C. 
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Pemphigoid Sera 
Serum from all 9 BP patients was obtained at the time of biopsy 
heat-inactivated (56°C X 30 min) and stored forzen in 1.0 ml aliquots 
al-70°C. 
Serum Complement 
Fresh frozen, platelet-poor normal human serum (NHS) from a 
single blood group AB, type Rh positive donor was used as a source of 
serum C in all studies. Blood was coUected under sterile conditions and 
platelet-poor serum prepared as previously described [10]. NHS was 
divided into 1.0 ml aliquots and stored froze n at -70°C. In some 
experiments heat-inactivated (56°C X 30 min) NHS was prepared from 
fresh NHS immediately before use. 
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Peripheral Blood Leukocytes (PBL) 
PBL from normal human volunteers were prepared by dextran 
sedimentation of heparinized whole blood using a previously described 
method [10]. Following dextran sedimentation for 30 min at 37°C, the 
leukocyte-rich supernate was removed and cells washed X2 in 20.0 ml 
Geys balanced salt solution (Flows Labs, McLean, VA) containing 2% 
bovine serum albumin (GBSS + 2%) BSA). Residual red cells were 
removed by hypotonic lysis with distilled water. Total leukocytes and 
, viability were determined by counting trypa n blue-stained cells in a 
hemocytometer. Viability was consistently greater than or equal to 
98%. The percentage of granulocytes determined by differential counts 
on 200 cells was consistently between 70 and 85%. 
Immunofluorescent Technique 
Direct immunofluorescence for IgG and C3 was performed on all BP 
skin using the methods of Beutner and Nisengard [13]. Indirect im-
munofluorescence for lgG anti-BMZ antibodies and indirect comple-
ment-binding immunofluorescence for C3-binding anti-BMZ antibodies 
were performed using normal human skin as substrate according to the 
method of Jordon, Sams, and Beutner [5]. Antisera used were fluOl·es-
cein isothiocyanate (FITC)-conj ugated goat anti-human lgG and C3 
(Cappel Labs, Cochranville, PA). Total protein concentration and 
molar fluorescein to protein (F / P) ratio for anti-C3 were 3,000 1-1g/ ml 
and 2.0 respectively. For anti-IgG, specific antibody concentration and 
F ; P ratio were 610 1-1g/ml and 2.6. Antisera were used at a working 
dilution of 1:10. The intensity of direct immunofluorescent stain ing wa 
graded by using an arbitrary scale of 0-4+. Anti-BMZ antibody titers 
in BP sera were the highest serum dilutions producing l+ BMZ 
fluorescence . Sera were not diluted beyond 1:1280. All immunofluores-
cence was performed using a Leitz Orthoplan fluorescent microscope 
eq uipped with epi-illumination. 
Leukocyte Attachment Method 
Three-four 8 J.Lm sections of skin were cut from each skin sample at 
-20°C on a Harris model WRC cryostat (Harris Manufacturing CO., 
Inc., Cambridge, MA) and placed approximately 4-mm apart in the 
center of gelatin-coated microscope slides. The tissue was allowed to 
dry briefly at 25°C and then washed for 10 min at 4°C in 0.15 M NaCI 
buffered with 0.01 M NatHPO,. and 0.01 M NaH"PO,,, pH 7.2 (PBS). 
Excess buffer was blotted from the slides and tissue chambers prepared 
as previously described [9]. Briefly, the tissue-slide was covered by a 
second slide to which 2 thicknesses of vinyl tape (Fisher Scientific Co) 
had been attached at each end. This prevented the covering slide from 
making direct contact with the tissue sections and provided a chamber 
between the slides 0.2 mm thick and 0.4 ml volu me. The tissue and 
covering slides were then taped together using Highland 6200 cello-
phane tape (3M Co., St. Paul , MN), and immediately placed in a 
humidity chamber at 25°C to prevent tissue sections from drying out. 
Slides were removed from the chamber as needed and each was injected 
with a supsension of 10 X 10" PBL/ ml in 5% NHS or 5% heat-inactivated 
(56°C X 30 min) NHS diluted in GBSS + 2% BSA. T he suspension was 
injected slowly over tissue sections with a tubercu lin syringe equipped 
with a 27-gauge needle taking care to avoid air bubbles, to avoid 
distw·bing tissue sections and to completely fill chambers. Slide cham-
bers were then incubated for min at 37°C in a humidified ambient air 
incubator. Following incubation slides were disassembled , excess serum 
and nonadherent ceUs 1·emoved by rinsing slides for 10 min in PBS and 
air-dried briefly at 25°C. Tissues were then fixed in 100% ethanol, 
stained with hematoxylin and eosin (H & E) and examined at 250x 
with a Zeiss light microscope equ ipped with an eyepiece linear microm-
eter (American Optical Corp., Buffalo, NY). 
Assessment of Leulwcyte Attachment and Compula.l ion of Results 
Leukocyte attachment was performed on at least 2 separate occa-
sions for each of the 29 skin samples in groups BPL, BPN, and NS. It 
was performed twice on 12 and once on 2 samples in group DS. For 
each assay, the 2 best skin sections on each slide (those howing 
minimal distortion of the BMZ) were counted. Frequently 1 or 2 of the 
3-4 sections originally placed on slides were torn or distorted preventing 
reliable counting of ceUs. For the 2 selected sections, 2-3 1000 1-1111 
segments of BMZ per section were selected at random and the number 
of PBL attached to the BMZ counted. An average LA valu e per 1,000 
J1II1 of BMZ was then computed for each assay by totaling the number 
of cells counted on sections and dividing by the number of 1,000 1-1 
segments counted. An average LA value for each skin biopsy was then 
calculated by adding the average for each assay and dividing by the 
number of assays performed on that biopsy. Mean attachment va lues 
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for each group of biopsies were calculated on the basis of the average 
LA value for each biopsy in the group. Statistical analysis of data was 
performed using the pai1·ed t-test, analysis of variance, correlation co-
efficients and chi-squru·e analysis. 
RESULTS 
Immunofluorescence 
The results of direct immunofluorescence for IgG and C3 at 
the BMZ in paired lesional and normal-appearing BP skin a1·e 
shown in Table I. IgG was detected at the BMZ in 8 of 9 
biopsies in group BPL and 5 of 9 in group BPN. Chi-square 
analysis of the incidence of IgG and C3 between groups showed 
no significant differences (p > .1). A comparison (paired t-test) 
of the mean intensity of immunofluorescent staining for IgG 
and C3 between groups also showed no significant difference. 
Results of indirect immunofluorescence for IgG and C3-binding 
anti-BMZ antibody titers for BP patients are also shown in 
Table I. Six of 9 sera had IgG anti-BMZ antibody activity at 
titers of 1:40 to 1:1280. Five of the 6 also had complement-
binding anti-BMZ antibodies at titers of 1:20-1:640. 
Results of Leulwcyte Attachment 
Table II shows the number of LA assays performed (column 
A) the number of 1000 !lm segments of skin examined (column 
B) and the average LA value (column C) for each of the 43 
biopsies in groups BPL, BPN, NS, and DS. The mean number 
of leukocytes attached per 1,000 !lm BMZ for lesiona1 BP skin 
(BPL) was 26.5, for adjacent normal-appearing skin (BPN)-8.9, 
for the normal control group (NS)-6.6 and for nonpemphigoid 
disease control group (DS)-8.2. Analysis of variance between 
the means of the 4 groups showed significantly greater attach-
ment in group BPL than in groups BPN, (p < .02) NS (p < .01) 
and DS (p < .02). No significant differences were observed 
between the m eans of groups BPN, NS, and DS. 
An analysis of the distribution of LA values for biopsies in 
group BPL and corresponding values for paired biopsies in 
group BPN (Fig 1) showed that in all patients, attachment was 
greater in lesional skin than in paired normal-appearing skin. 
Evidence supporting a requirement for serum complement in 
attachment of leukocytes to BP lesional skin: The LA assay 
was performed on lesiona1 BP skin sections from 5 biopsies on 
4 patients (patients number 5, 6, 7, 9) using cells suspended in 
either 5% NHS or 5% heat-inactivated (56°C X 30 min) NHS) . 
These experiments were performed in duplicate. The results 
(Fig 2) showed a significant reduction in attachment in the 
presence of heat-inactivated (56°C x 30 min) NHS compared 
to NHS (p < .05). 
Inhibition of LA by F(ab) 2 antibody to the Fe fragment of 
human IgG. In duplicate experiments skin sections from the 
lesional skin of 3 BP patients were preincubated for 30 min at 
4 oc with a 1:10 dilution of the F(ab'h fragment of goat IgG 
with specificity for the Fe fragment of human IgG (Cappel 
Labs). The anti-human Ig:G Fe was used at a concentration of 
0.5 mg/ ml antibody protein. Control sections r eceived incuba-
tion with buffer alone. Following incubation, sections were 
rinsed in PBS and the LA procedure performed. Results, Table 
III, showed significant inhibition of LA in sections treated with 
antibody to human IgG (Fe) compared to sections treated with 
buffer alone (p <s .02) . 
Comparison between LA and R esults of Direct and Indirect 
Immunofluorescence 
To determine if a relationship between LA values and inten-
sity of immunofluorescence was present in BP biopsies, LA in 
each of the biopsies in groups BPL and BPN was compared 
with the respective intensity (0-4+) of direct immunofluores-
cence for both IgG and C3. The results showed no correlation 
for any of the comparisons. Furthermore, no correlation was 
observed between the level of LA and titers of IgG or C3-
binding anti-BMZ antibodies. 
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TABLE L Results of immunofluorescence for IgG and C3 deposits in skin and lgG anti-BMZ antibodies and complement-binding an tibodies 
in sera of pemphigoid patients 
Patient Lesion a! (BPL) Normal (BPN)" l gG Anti -BMZ C3-Binding skin l gG C3 skin lgG C3 antihody titers tilers 
3+ 4+ 3+ 4+ > 12801' 160 
2 3+ 4+ 0 2+ < 10 < 10 
3 2+ 4+ 0 2+ 80 < 10 
4 4+ 4+ 3+ 2+ 160 40 
5 4+ 4+ 2+ 2+ >1280 640 
6 2+ 2+ 2+ 3+ 320 320 
7 0 3+ 0 0 < 10 > 10 
8 1+ 2+ 0 1+ 40 20 
9 3+ l+ 3+ 2+ < 10 10 
Mean 2.4 3.1 1.4 2.0 251 131 
Incidence 89% 100% 56% 89% 
" Biopsies of normal skin were taken approximate ly 2 em from the site of lesional skin biopsies. 
1
' Ti ters 10 or 1280 were no t determined. 
,. 0 = no staining; 1+ =trace discont inuous staining; 2+ =trace continuous; 3+ = moderate staining; 4+ = heavy staining. 
TABLE II. R esults of leukocyte attachment in. bullous pemphigoid lesional (BPL) and paired normal-appearing shin (BPN), normal shin 
(NS) and disease control shin (DS) groups 
Sam- BPL BPN NS DS 
pie 
B'' # A" C' A ..B c A B c A B c 
] 
--6 -r8 17.0 3 19 9.5 2 12 5.2 2 12 14.6 
2 2 9 10.8 2 12 6.6 2 12 4.4 2 12 6.6 
3 3 18 34.2 2 12 10.6 2 12 4.0 2 12 12.4 
4 3 15 30.9 3 18 6.4 2 12 3.4 1 6 5.0 
5 3 20 24 .4 2 9 16.1 2 12 6.6 2 12 8.8 
6 2 12 23.8 2 12 10.4 2 12 6.8 2 12 7.9 
7 2 11 32.7 2 12 4.6 2 12 8.7 2 12 6.6 
8 2 9 36.4 2 12 9.0 2 12 10.4 2 12 6.9 
9 2 12 28.2 2 13 7.1 2 12 5.5 2 12 7.2 
10 2 12 5.1 2 12 7.1 
11 2 12 12.1 2 12 7.1 
12 2 12 5.2 
13 2 12 7.2 
14 1 6 12.0 
Tolals 22 124 238.4 20 119 80.3 22 132 72.2 26 156 115. 
Means 2.4 13.8 26.5 2.2 13.2 
"Number of assays. 
1
' Total number of 1,000 J.Lm segments of BMZ coun ted: 
,. Average number of Jeukocytes/1000 p.m BMZ for all sections. 
DISCUSSION 
Since the initial reports that patients with BP have immune 
reactants at the BMZ, there has been speculation that they are 
components of immune complexes arui~rt'l'i.nt i n causing 
_ ~;.uta.neous infbmnnation. "S upporting the hypothesis is: (1) the 
similarity of BMZ deposits to those seen in animal models of 
experimental antibasement membrane nephl'itis [1], (2) the 
finding that most patients have anti-BMZ antibiodies that will 
activate and deposit multiple components of the classical and 
alternative C pathways in the identical ultrastructural location 
occupied by in vivo deposited lg and C (14-20], (3) the presence 
of multiple components of Cat the BMZ in patients skin which 
strongly suggests sequential activation rather than random or 
nonspecific deposition [6,12,21,22] and studies of C components 
in blister fluids which have reported consumption and activa-
tion of C and production of biologically-active factors with 
chemotactic and possibly anaphylatoxic properties [6-8,23,24). 
Nevertheless, there has been difficulty in providing functional 
support for an immune complex mediated pathogenesis of BP. 
For example, it has not been possible to passively transfer 
blisters or inflammation to animals with BPS containing high 
titer anti-BMZ antibodies and to date no in vitro model of the 
disease has been reported (1). Furthermore, difficulties in ac-
cepting an immune complex pathogenesis have been due in part 
to the inab ility to directly show that immune reactants in BP 
skin possess functional properties that could contribute to 
inflammation. 
8.9 2 12 6.6 1.8 11.1 8.2 
Until recently, methods for demonstrating immune complex 
fun ction in tissue had not been described and thus then· pres-
ence was implied primaTily by labeled antibody methods such , 
as immunofluorescence. Although the methods can identify 
"components" of complexes, e.g. , Ig, C and in some cases antigen 
and have been extremely useful in disease diagnosis and point-
ing out possible pathologic mechanisms, they have 2 important 
limitation: inability to (1) detect and (2) quantitate immune 
complex activity. 
R ecently, Yamamoto et a! described a method for detecting 
and quantitating C-activating complexes deposited in animal 
tissue in vivo [11). These workers used cryostat sections of 
kidneys from rats with experimental immune complex glomer-
ulonephritis as a SOUl'ce of tissue deposited complexes. When 
sections of normal kidney and kidney con taining glomerular 
deposits of IgG and C3 were incubated with rat peritoneal 
leukocytes suspended in fresh rat serum, cells attached specif-
ically only to kidney sections containing immune reactants. 
Although the mechanism of LA was not completely defined, it 
was shown that cells attached to the exact site (glomeruli) of 
immune reactant deposition, only to glomeruli containing Ig 
and C and demonstrated that a source of exogenous (serum) 
complement was required. When rat serum was heat-inacti· 
vated (56 °C X 30 min) or absorbed with anti-C3 globulin 
attachment did not occur. Furthermore, these authors showed 
that the number of cells attached was proportional to the extent 
of morphologic glomerular damage and, to some extent, the 
intensity of lgG and C3 immunofluorescence. 
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Using a modification of the method, we recently reported 
that human PBL suspended in fresh NHS would attach to the 
BMZ of cryostat sections of normal human skin which had 
been treated with BPS containing C-binding anti-BMZ anti-
boclies [9,10]. Evidence that cells were attaching to comple-
ment-activating immune complexes was supported by the find-
ings t hat (1) only BPS or IgG fractions of BPS containing C-
binding anti-BMZ antibodies mediated the reaction; (2) a strong 
correlation existed between titers of C-binding anti-BMZ anti-
bodies and LA titers and (3) attachment occurred in the pres-
ence of fresh NHS, and C2-deficient serum reconstituted with 
purified C2 but not with heat-inactivated NHS, decomple-
mented NHS or C2-deficient serum alone. FUJ"thermore, using 
a modification of the method, it was possible to show that the 
mech anism of a ttachment involved the complement-dependent 
directed migration of cells to the BMZ followed by immune 
adherence. The studies on the detection of in vivo deposited 
immune complexes by Yamamoto et al. and studies on human 
skin noted above suggested LA would be an effective method 
for evaluation of in vivo-deposited immune reactants in BP. 
Using the method to investigate the activity of immune 
reactants in the skin of patients with BP, the following obser-
vations were made: (1) there was significantly greater attach-
ment of leukocytes to the BMZ of lesional BP skin compared 
to normal BP skin, normal skin and skin from patients with a 
variety of inflammatory diseases not as~ociated with immune 
deposits at the BMZ; (2) LA in lesional BP skin was significantly 
reduced when cells were suspended in heat-inactivated NHS 
rather than fresh NHS and when sections were pretreated with 
anti-human IgG (Fe) to block the complement activating site of 
complexes and (3) of possible importance, LA was not signifi-
cantly different in normal BP skin compared to the 2 control 
groups. 
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x 30 min) serum on leukocyte attachment to the BMZ. The points 
connected by lines represent the same biopsy assayed for LA wit.h NHS 
and with heat-inactivated NHS. 
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TABLE III. R esults of leulwcyte attachment in lesional BP shin 
following pretreatment of tissue sections with Fab goat anti-human 
JgGFc 
BPL skin 
LA (PF'L/ 1.000 I"" BMZ) 
F'a b goat/ human 
IgG Fe Buffer 
2 
3J. 
20.0 
19.0 
19.3 
36.0 
35.7 
30.3 
Mean± SD 19.4 ± 0.4 34 .0 ± 2.3 
BPL: Lesional BP Skin. 
The first two observations provided evidence for the presence 
of C-activating IgG immune complexes in the lesions of patients 
with BP. This conclusion is supported by the presence of IgG 
and C3 at the BMZ, the apparent requirement for serum C in 
the attachment reaction and inhibition of LA by antibody to 
human IgG (Fe). Although IgG immune complex-mediated C-
activation is the most likely mechanism of attachment, other 
possibilities were considered. 
Factors other than C-activating IgG immune complexes and 
present only in or at higher activity in lesional BP skin could 
have caused LA. Tissue proteases with serine esterase activity 
such as plasmin which can cleave Clr , Cis, C3 and C5 (15] and 
an epidermal cell protease which has been shown to cleave C5 
releasing C5a chemotactic activity could presumably cause 
ieukocyte attachment [26). Although these enzymes could ac-
count for the requirement for C, we feel this mechanism is 
unlikely because: (1) all tissues were washed in buffer prior to 
incubatio n with cells and serum, (2) there is no known reason 
why the activity of these proteases should be localized to the 
BMZ and (3) most importantly, significant attachment was not 
observed in either normal or nonpemphigoid inflammed skin . 
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This observation suggests proteases released or activated in 
damaged (freeze-thawed and cut) normal skin or present in 
inflammed skin are not sufficient to account for the attachment 
observed in lesional BP skin. Furthermore, this mechanism of 
attachment would not be expected to be inhibited by anti-
human lgG Fe. 
Another possibility is that immune complexes other than 
those containing lgG were present at the BMZ. This could 
account for C activation and attachment of leukocytes to the 
BMZ and could explain the lack of a correlation between results 
of LA and IgG immunofluorescence. Although this possibility 
cannot be excluded it has been shown in several studies that Ig 
deposits other than IgG are relatively uncommon in BP skin 
[6,21,22,27). Furthermore, in 6/9 cases examined here, IgM and 
IgA immunofluorescence were negative in both lesional and 
normal skin (results not shonw). Against this possibility also is 
the fmding that LA was blocked by anti-human lgG (Fe). It is, 
of course, conceivable that antibody not detectable by immu-
nofluorescence accounted for attachment since attachment was 
seen in the lesional skin of case 7 in which no IgG was observed. 
In this regard it is known that anti-BMZ antibodies including 
those present in BP and herpes gestationis sera can bind C to 
the BMZ in vitro in the absence of detectible antibody binding 
[28,29). 
Functional components of the C system deposited at the 
BMZ in vivo could also account for the attachment of cells to 
the BMZ. If; for example, functional C3 or C5 convertases such 
as C42, C423b or C3bBb were present in lesional skin, they 
could presumably utilize exogenous C3 or C5 as substrate to 
form additional convertase activity, deposit membrane bound 
C3B, generate C5 cleaving activity and cleave C5 to C5a causing 
the migration and attachment of cells [25). Supporting this 
concept is a report suggesting that C3b may be present in 
lesional but not normal BP skin [30). 
Although LA was significantly greater in lesional compared 
to normal BP skin, no significant differences in either the 
intensity or incidence of IgG or C3 immunofluorescence be-
tween the groups was observed. Furthermore, no correlations 
were found between the level of LA and the intensity of im-
munofluorescence in any of the BP tissues. These results 
strongly suggest that conclusions about the presence of func-
tional immune complexes in BP cannot be based on immuno-
fluorescent results alone. 
The lack of agreement between the immunofluorescence and 
LA assays was somewhat unexpected but not totally surprising 
since they appear to measure or detect different things. Im-
munofluorescence detects lg or C simply as an antigen, the 
intensity of which is determined by the total amount of antigen 
present. LA on the other hand presumable detects physiological 
activity which is determined not by the total amount of Ig but 
the amount that is functional (C-activating) . Since immune 
complexes may contain C-binding and non C-binding subclasses 
of Ig, differences in the relative amounts of C-binding IgG in 
BP tissues could explain the lack of agreement between the 
methods. 
It is possible that as yet undetermined factors which could 
enhance the immune complex-mediated activation of C in le-
sional skin or alternatively inhibit, block or saturate this activity 
in normal BP skin could account for the discrepancies between 
immunofluorescence and LA. These questions will require ad-
ditional studies and perhaps new methods of immune complex 
analysis. 
In conclusion, we feel these studies do provide functional 
evidence for the presence of C-activating immune complexes in 
the lesional skin of patients with BP. This finding suggests 
complexes are important in cutaneous inflammation and is 
consistent with, though certainly does not prove, an immune 
complex pathogenesis of the disease. In addition, the finding 
that LA is greater in lesional than normal BP skin and that LA 
activity in normal BP skin is not significantly different from 
Vol. 78, No. 1 
normal human skin suggest immune complex function may be 
a reason why lesions develop at some sites and not others. It is 
anticipated that further studies using the LA method will be 
useful not only in defining the role of IC in the pathogenesis of 
BP, but in other suspected immune complex-mediated disease 
as well. 
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